Cargando…

Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study

The therapeutic approach of bladder cancer strongly determines its prognosis. We describe the treatments and outcomes for a Spanish cohort of patients with bladder cancer for the first 12 months after diagnosis and identify the factors that influenced the decision to undergo the treatment received....

Descripción completa

Detalles Bibliográficos
Autores principales: Bonfill, Xavier, Martinez-Zapata, María José, Barrionuevo-Rosas, Leslie, Vernooij, Robin WM, Sánchez, María José, Morales-Suárez-Varela, María, De la Cruz, Javier, Emparanza, José Ignacio, Ferrer, Montserrat, Pijoan, José Ignacio, Palou, Joan, Frances, Albert, Madrid, Eva, Coscia, Claudia, Zamora, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592268/
https://www.ncbi.nlm.nih.gov/pubmed/36281169
http://dx.doi.org/10.1097/MD.0000000000031175
_version_ 1784814886112460800
author Bonfill, Xavier
Martinez-Zapata, María José
Barrionuevo-Rosas, Leslie
Vernooij, Robin WM
Sánchez, María José
Morales-Suárez-Varela, María
De la Cruz, Javier
Emparanza, José Ignacio
Ferrer, Montserrat
Pijoan, José Ignacio
Palou, Joan
Frances, Albert
Madrid, Eva
Coscia, Claudia
Zamora, Javier
author_facet Bonfill, Xavier
Martinez-Zapata, María José
Barrionuevo-Rosas, Leslie
Vernooij, Robin WM
Sánchez, María José
Morales-Suárez-Varela, María
De la Cruz, Javier
Emparanza, José Ignacio
Ferrer, Montserrat
Pijoan, José Ignacio
Palou, Joan
Frances, Albert
Madrid, Eva
Coscia, Claudia
Zamora, Javier
author_sort Bonfill, Xavier
collection PubMed
description The therapeutic approach of bladder cancer strongly determines its prognosis. We describe the treatments and outcomes for a Spanish cohort of patients with bladder cancer for the first 12 months after diagnosis and identify the factors that influenced the decision to undergo the treatment received. We conducted a multicenter, prospective, cohort study including primary bladder cancer patients during the first 12 months after diagnosis. The clinical outcomes were performance status (ECOG), adverse events and any cause of mortality. We stratified the analysis by factors that might influence the treatments received. We conducted univariate and multivariable logistic regression models to assess which patient and tumor characteristics were associated with receiving adjuvant treatment in the subgroup of noninvasive bladder cancer patients. In total, 314 patients were included (85% men; 53.8% >70 years) in 7 tertiary Spanish hospitals; 82.2% had a noninvasive urothelial bladder cancer (NMIBC). Patients received mostly surgery plus adjuvant therapy (67.7%). BCG (32.8% patients) was the most frequently administered adjuvant therapy, followed by intravesical chemotherapy (17.8% patients) and radiotherapy (10.8%). The variability of administered treatments among hospitals was low. Patients with NMIBC were more likely to receive adjuvant therapy if they had a higher educational level, some comorbidities and a high-grade tumor. The number of fully active patients (ECOG 0) significantly decreased during the first year of follow-up from 58% to 36 % (OR: 2.41, 95%CI 1.82–3.20); at 12-month follow-up 10.8% patients had died from any cause. In conclusion, most of the patients had a NMIBC. Surgery alone or plus adjuvant therapy were the commonest curative options of bladder cancer. BCG therapy was the adjuvant therapy most frequently administered. Higher educational level, presence of comorbidities and a high-grade tumor were associated with adjuvant therapy. Patient performance status was worsening over time. Almost 1 of 10 patients died during the first year of follow-up.
format Online
Article
Text
id pubmed-9592268
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95922682022-10-25 Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study Bonfill, Xavier Martinez-Zapata, María José Barrionuevo-Rosas, Leslie Vernooij, Robin WM Sánchez, María José Morales-Suárez-Varela, María De la Cruz, Javier Emparanza, José Ignacio Ferrer, Montserrat Pijoan, José Ignacio Palou, Joan Frances, Albert Madrid, Eva Coscia, Claudia Zamora, Javier Medicine (Baltimore) 7300 The therapeutic approach of bladder cancer strongly determines its prognosis. We describe the treatments and outcomes for a Spanish cohort of patients with bladder cancer for the first 12 months after diagnosis and identify the factors that influenced the decision to undergo the treatment received. We conducted a multicenter, prospective, cohort study including primary bladder cancer patients during the first 12 months after diagnosis. The clinical outcomes were performance status (ECOG), adverse events and any cause of mortality. We stratified the analysis by factors that might influence the treatments received. We conducted univariate and multivariable logistic regression models to assess which patient and tumor characteristics were associated with receiving adjuvant treatment in the subgroup of noninvasive bladder cancer patients. In total, 314 patients were included (85% men; 53.8% >70 years) in 7 tertiary Spanish hospitals; 82.2% had a noninvasive urothelial bladder cancer (NMIBC). Patients received mostly surgery plus adjuvant therapy (67.7%). BCG (32.8% patients) was the most frequently administered adjuvant therapy, followed by intravesical chemotherapy (17.8% patients) and radiotherapy (10.8%). The variability of administered treatments among hospitals was low. Patients with NMIBC were more likely to receive adjuvant therapy if they had a higher educational level, some comorbidities and a high-grade tumor. The number of fully active patients (ECOG 0) significantly decreased during the first year of follow-up from 58% to 36 % (OR: 2.41, 95%CI 1.82–3.20); at 12-month follow-up 10.8% patients had died from any cause. In conclusion, most of the patients had a NMIBC. Surgery alone or plus adjuvant therapy were the commonest curative options of bladder cancer. BCG therapy was the adjuvant therapy most frequently administered. Higher educational level, presence of comorbidities and a high-grade tumor were associated with adjuvant therapy. Patient performance status was worsening over time. Almost 1 of 10 patients died during the first year of follow-up. Lippincott Williams & Wilkins 2022-10-21 /pmc/articles/PMC9592268/ /pubmed/36281169 http://dx.doi.org/10.1097/MD.0000000000031175 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 7300
Bonfill, Xavier
Martinez-Zapata, María José
Barrionuevo-Rosas, Leslie
Vernooij, Robin WM
Sánchez, María José
Morales-Suárez-Varela, María
De la Cruz, Javier
Emparanza, José Ignacio
Ferrer, Montserrat
Pijoan, José Ignacio
Palou, Joan
Frances, Albert
Madrid, Eva
Coscia, Claudia
Zamora, Javier
Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study
title Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study
title_full Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study
title_fullStr Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study
title_full_unstemmed Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study
title_short Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study
title_sort follow-up care of 12 months of patients with bladder cancer in spain: a multicenter prospective cohort study
topic 7300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592268/
https://www.ncbi.nlm.nih.gov/pubmed/36281169
http://dx.doi.org/10.1097/MD.0000000000031175
work_keys_str_mv AT bonfillxavier followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT martinezzapatamariajose followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT barrionuevorosasleslie followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT vernooijrobinwm followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT sanchezmariajose followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT moralessuarezvarelamaria followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT delacruzjavier followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT emparanzajoseignacio followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT ferrermontserrat followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT pijoanjoseignacio followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT paloujoan followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT francesalbert followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT madrideva followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT cosciaclaudia followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy
AT zamorajavier followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy